Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raymond L Comenzo

Showing results (51-60 of 87) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaMelissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Blood|June 6, 2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyDonna E Reece, Vaishali Sanchorawala, Ute Hegenbart, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 10, 2017
Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single CenterSandy W Wong, Denis Toskic, Melissa Warner, et al.
Gene Therapy|March 31, 2019
A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseasesXun Ma, Ping Zhou, Adin Kugelmass, et al.
Frontiers in Cardiovascular Medicine|December 31, 2024
Case Report: Avoiding misdiagnosis in amyloidosis-navigating transthyretin genopositivity and monoclonal gammopathy in a patient with advanced heart failure and spinal stenosisXia Wu, Denis Toskic, Ping Zhou, et al.
Blood|January 25, 2008
CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyPing Zhou, Raymond L Comenzo, Adam B Olshen, et al.
Leukemia & Lymphoma|August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary diseaseHeather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.
British Journal of Cancer Research|January 10, 2025
Seeking Amyloidosis Very Early: Free light Chain Differentials and IGLV Gene Use as Screening Variables for Light-chain Amyloidosis in λ Monoclonal GammopathiesPing Zhou, Mahesh M Mansukhani, Raymond Yeh, et al.
Experimental Hematology & Oncology|October 26, 2018
Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growthXun Ma, Sandy W Wong, Ping Zhou, et al.
Pageof 9

Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2012
A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphomaMelissa Alsina, Suzanne Trudel, Richard R Furman, et al.
Blood|June 6, 2009
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation studyDonna E Reece, Vaishali Sanchorawala, Ute Hegenbart, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 18, 2021
Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple MyelomaAndrzej Jakubowiak, Saad Z Usmani, Amrita Krishnan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 10, 2017
Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single CenterSandy W Wong, Denis Toskic, Melissa Warner, et al.
Gene Therapy|March 31, 2019
A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseasesXun Ma, Ping Zhou, Adin Kugelmass, et al.
Frontiers in Cardiovascular Medicine|December 31, 2024
Case Report: Avoiding misdiagnosis in amyloidosis-navigating transthyretin genopositivity and monoclonal gammopathy in a patient with advanced heart failure and spinal stenosisXia Wu, Denis Toskic, Ping Zhou, et al.
Blood|January 25, 2008
CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyPing Zhou, Raymond L Comenzo, Adam B Olshen, et al.
Leukemia & Lymphoma|August 10, 2011
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary diseaseHeather Landau, Neeta Pandit-Taskar, Hani Hassoun, et al.
British Journal of Cancer Research|January 10, 2025
Seeking Amyloidosis Very Early: Free light Chain Differentials and IGLV Gene Use as Screening Variables for Light-chain Amyloidosis in λ Monoclonal GammopathiesPing Zhou, Mahesh M Mansukhani, Raymond Yeh, et al.
Experimental Hematology & Oncology|October 26, 2018
Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growthXun Ma, Sandy W Wong, Ping Zhou, et al.
Pageof 9